2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove OutcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed modelsExtrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansConclusion and implications for practice and policy
Rosenheck R, Stroup T, Lieberman J. Conclusion and implications for practice and policy. 2010, 288-306. DOI: 10.1017/cbo9780511712265.018.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansFamily outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisClinicians
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia